NP5 Newron Pharmaceuticals S.p.A.

XETRA · DE · Healthcare · Biotechnology · newron.com

8.360EUR-2.11%Mkt Cap: 185.81M $P/E: —Today

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago …

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap185.81M USD

Enterprise Value199.81M USD

Revenue (TTM)11.32M USD

Gross Profit11.32M USD

Net Income (TTM)-14.39M USD

Revenue/Share0.52 EUR

Last Price8.360 EUR

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees27

CountryDE

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA-8.13

EV/Revenue17.65

P/S16.76

P/B-15.36

EPS (TTM)-1.46

EPS (Forward)—

52W Range

8.1801% of range34.65

52W High34.65 EUR

52W Low8.180 EUR

Profitability

Gross Margin100.00%

Oper. Margin-520.54%

EBITDA Margin-217.13%

Profit Margin-69.22%

ROE118.90%

ROA-33.05%

Growth

Revenue Growth-73.20%

Earnings Growth—

Cash Flow & Leverage

Operating CF35.16M USD

CapEx (TTM)52.17K USD

FCF Margin14.84%

FCF Yield0.90%

Net Debt6.68M USD

Net Debt/EBITDA-0.27

Balance Sheet

Debt/Equity-3.43

Current Ratio3.15

Quick Ratio2.89

Book Value/Sh-0.56 EUR

Cash/Share1.58 EUR

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 EUR

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.20.45M

Float18.87M

Insiders12.84%

Institutions12.49%

Technical

SMA 5012.34 (-32.2%)

SMA 20016.67 (-49.8%)

Beta0.73

S&P 52W Chg14.58%

Avg Vol (30d)8.30K

Avg Vol (10d)10.70K

Technical Indicators

RSI (14)26.4

MACD-1.0961

MACD Signal-0.7765

MACD Hist.-0.3196

BB Upper14.27 EUR

BB Middle11.10 EUR

BB Lower7.921 EUR

BB Width57.22%

ATR (14)0.6880 EUR

Vol Ratio (20d)0.63x